As shown in Figure 6C, the degree of PAI-1 expression was significantly higher in the tumor after acquired resistance to EGFR-TKI than during pretreatment (PAI-1-positive areas of 2.5% vs. 24.1%, respectively, p < 0.05). This evidence concerns the gene EGFR and neoplasm.